Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
News
Market Highlights: ASX set for a quietly sub-optimal open after tech took a breather in the US
Health & Biotech
ASX Health Stocks: Anteris’ 3D heart valve shows consistent results; as Nyrada announces a new lead drug
Health & Biotech
ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
News
In Case You Missed It: Lithium, lithium, some cannabis … and more lithium
Health & Biotech
ASX Health Stocks: Imugene’s liver cancer platform presented at prestigious conference
News
ASX Small Caps Lunch Wrap: Who else is crying out for some decent proofreaders this week?
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
News
Market Highlights: Tesla’s margins collapse, big announcement on RBA today, and 5 ASX small caps to watch
Health & Biotech
ASX Health Stocks: Atomo and Volpara strike $1m+ contracts; Estia tells Bain to improve $3 offer
News
CLOSING BELL: At least it didn’t get any worse after lunch… right?
News
ASX Small Caps Lunch Wrap: Who else is singin’ the blues as the market sinks today?
News
Market Highlights: Wall Street slumps, while RBA could trigger ‘volatility’ on the ASX today
News
ASX Small Caps Lunch Wrap: Who’s trying to revive the grand traditions of the carrier pigeon?
News
CLOSING BELL: First we were soaring, then we were snoring as the benchmark runs out of puff post-lunch
News